Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression >= 5%

This is written in the approval document.

Reimbursement

ODMS

Citation

Atezolizumab 1680mg Monotherapy - 28 Day, 2020, version number 1, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6399/593_v10a_Atezolizumab_1680mg_Monotherapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	PD-L1 >= 5%	Bladder Urothelial Carcinoma	Atezolizumab